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ORIGINAL INVESTIGATION
Dapagliflozin acutely improves 
endothelial dysfunction, reduces aortic stiffness 
and renal resistive index in type 2 diabetic 
patients: a pilot study
Anna Solini1* , Livia Giannini2, Marta Seghieri2, Edoardo Vitolo2, Stefano Taddei2, Lorenzo Ghiadoni2 
and Rosa Maria Bruno2
Abstract 
Background: Sodium-glucose cotransporter-2 inhibitors reduce blood pressure (BP) and renal and cardiovascular 
events in patients with type 2 diabetes through not fully elucidated mechanisms. Aim of this study was to investigate 
whether dapagliflozin is able to acutely modify systemic and renal vascular function, as well as putative mechanisms.
Methods: Neuro-hormonal and vascular variables, together with 24 h diuresis, urinary sodium, glucose, isoprostanes 
and free-water clearance were assessed before and after a 2-day treatment with dapagliflozin 10 mg QD in sixteen 
type 2 diabetic patients; data were compared with those obtained in ten patients treated with hydrochlorothiazide 
12.5 mg QD. Brachial artery endothelium-dependent and independent vasodilation (by flow-mediated dilation) and 
pulse wave velocity were assessed. Renal resistive index was obtained at rest and after glyceryl trinitrate administra-
tion. Differences were analysed by repeated measures ANOVA, considering treatment as between factor and time as 
within factor; Bonferroni post hoc comparison test was also used.
Results: Dapagliflozin decreased systolic BP and induced an increase in 24 h diuresis to a similar extent of hydrochlo-
rothiazide; 24 h urinary glucose and serum magnesium were also increased. 24 h urinary sodium and fasting blood 
glucose were unchanged. Oxidative stress was reduced, as by a decline in urinary isoprostanes. Flow-mediated dila-
tion was significantly increased (2.8 ± 2.2 to 4.0 ± 2.1%, p < 0.05), and pulse-wave-velocity was reduced (10.1 ± 1.6 
to 8.9 ± 1.6 m/s, p < 0.05), even after correction for mean BP. Renal resistive index was reduced (0.62 ± 0.04 to 
0.59 ± 0.05, p < 0.05). These vascular modifications were not observed in hydrochlorothiazide-treated individuals.
Conclusions: An acute treatment with dapagliflozin significantly improves systemic endothelial function, arterial 
stiffness and renal resistive index; this effect is independent of changes in BP and occurs in the presence of sta-
ble natriuresis, suggesting a fast, direct beneficial effect on the vasculature, possibly mediated by oxidative stress 
reduction.
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Introduction
The interaction between renal hemodynamics and BP is 
a complex issue, and this balance plays a key role in the 
sodium and water reabsorption by renal tubule. A raise 
in systemic BP influences intraglomerular pressure; an 
elevated renal interstitial hydrostatic pressure, direct 
consequence of systemic hypertension, rapidly inhib-
its sodium reabsorption by the proximal tubule, and the 
kidney responds by increasing sodium excretion; how-
ever, physiological mechanisms governing this adaptive 
response are only partially clarified [1]. Endothelium 
takes part in this complex mechanism: it has been sug-
gested that pressure-mediated increases in vascular shear 
stress stimulate endothelial nitric oxide (NO) production, 
a signal able to reduce tubular sodium reabsorption [2, 
3]; moreover, reactive oxygen and nitrogen species are 
key modulators of the pressure-natriuresis response [4].
Sodium-glucose co-transporter-2 (SGLT2) inhibitors 
are a novel class of glucose-lowering agents used in the 
treatment of type 2 diabetes (T2D). By inhibiting the 
transporter protein SGLT2 in the kidney, they reduce 
renal glucose reabsorption, promoting its urinary excre-
tion. Unlike other oral antidiabetic drugs, the efficacy of 
these compounds is independent of insulin secretion and 
action [5], being exclusive function of plasma glucose lev-
els and glomerular filtration rate.
Given their selective action on a dual transporter, 
SGLT2 inhibitors are supposed to increase natriure-
sis; however, several studies have denied an increased 
sodium (Na) excretion during SGLT2 inhibition [6–8]; 
a hypothetic up-regulation of other Na transporters has 
been suggested to explain this clinical finding. No doubt 
a precise quantitation of Na balance requires stabilization 
of its intake over several days; however, gross changes in 
serum Na concentration do not seem usual with chronic 
SGLT2 inhibition. At the nephron level, reduced Na 
reabsorption in the proximal segment increases Na deliv-
ery to the juxtaglomerular apparatus, thereby inhibiting 
the renin-angiotensin-aldosterone system (RAAS) [9]. In 
diabetic rats fed with a high-salt diet, SGLT2 inhibition 
prevents BP increase [10]; this effect may be counter-
acted by an activation of the RAAS, induced by excessive 
diuresis and volume depletion [11]. However, the mecha-
nisms through SGLT2 inhibition reduce BP are not fully 
elucidated.
T2D patients show an impaired endothelial function, 
characterized by reduced NO availability, which can be 
demonstrated in peripheral arteries [12]; a further altera-
tion in endothelial function has been shown after salt 
loading [13]. Endothelial dysfunction contributes to the 
development of hypertension, thereby promoting car-
diovascular and renal damage [14]; therefore, improving 
endothelial function by restoring NO production with 
pharmacologic treatments may represent a useful tool 
and an important therapeutic goal in T2D [15]. The 
present study has been designed with the aim at evalu-
ating whether, in T2D patients, an acute SGLT2 inhibi-
tion might modulate BP-related vascular parameters, like 
endothelium-dependent or independent vasodilation, 
arterial stiffness and renal vascular function by non inva-
sive tests. As secondary endpoints, we explored RAAS 
and neuro-hormonal axis activation and oxidative stress 
as possible mechanism(s) concurring in explaining the 
vascular effects of dapagliflozin.
Methods
Subjects
Sixteen patients with T2D, consecutively recruited 
among those attending our diabetes outpatient’s clinic 
between January and September 2016 received dapa-
gliflozin. Inclusion criteria were age between 40 and 
70  years, BMI  <  40  kg/m2, an adequate glucose control 
 (HbA1c  <  64  mmol/mol) reached with any oral anti-
hyperglycemic drug, clinic BP values  <  140/90  mmHg, 
treatment-naïve status for high BP. Exclusion criteria 
were an established hypertensive status, a moderate to 
severe renal function impairment (estimated glomerular 
filtration rate—eGFR  <  60  ml/min/1.73  m2) and pres-
ence of clinically relevant cardiovascular/pulmonary/
haematologic/hepatic disease, insulin treatment. Given 
the relatively unexpected significant BP reduction after 
only 2 days of dapagliflozin treatment, ten T2D patients 
were selected after the completion of the sixteen cases on 
the basis of the same inclusion criteria; they followed the 
same protocol but receiving hydrochlorothiazide (HCT), 
and served as control group, to test whether the results 
obtained in cases could be specifically related to the 
mode of action of dapagliflozin or, more extensively, to its 
diuretic and BP-lowering effect. This was conceived as a 
pilot study aimed at testing the aforementioned working 
hypothesis and planning larger studies in the future.
The nature and purpose of the study were carefully 
explained to all subjects before they provided their writ-
ten consent to participate. The protocol was approved by 
the local Ethics Committee and registered in the Registry 
of the Italian Drug Agency (Agenzia Italiana del Farmaco, 
AIFA, #772/2015).
Study design and protocol
When screened for eligibility, selected participants were 
advised to keep a daily Na intake of 92 mmol for the week 
preceding the study and until the end of the experimen-
tal protocol. Each subject was studied twice as outpa-
tients: Visit 0, or baseline visit (day 0), and 2  days after 
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a treatment with dapagliflozin 10  mg or HCT 12.5  mg 
QD (Visit 1, day 3); we chose 48  h on the basis of the 
pharmacokinetic properties of dapagliflozin [16]. In 
both visits, blood and urinary samples were collected 
for routine analyses, and determinations of plasma renin 
activity, aldosterone, norepinephrine, epinephrine and 
24  h  urinary electrolytes and 8-isoprostane; a complete 
non-invasive vascular evaluation, including flow-medi-
ated dilation of the brachial artery (FMD), baseline and 
dynamic renal resistive index (RI), carotid-femoral pulse-
wave velocity (PWV) and augmentation index (AIx) were 
also performed. All vascular tests were carried out by the 
same physician, with a long-lasting experience in this 
field (RMB).
Endothelium‑dependent and ‑independent vasodilation 
in the brachial artery
Endothelium-dependent response was obtained by FMD, 
as previously described [17]. A longitudinal ultrasound 
scan of brachial artery was performed by using a high-
resolution ultrasound machine equipped with 10  MHz 
linear explorer (MyLab 25, ESAOTE Florence, Italy). 
After 1-min baseline recording, the cuff was inflated for 
5 min at 300 ± 30 mmHg around the forearm and then 
deflated to induce reactive hyperaemia. Endothelium-
independent vasodilation was obtained by the sublin-
gual administration of 25  μg glyceryl trinitrate (GTN). 
Brachial artery diameter and flow velocity were continu-
ously monitored by computerized edge detection sys-
tem (Cardiovascular Suite; Quipu srl, Italy). FMD and 
response to GTN were calculated as the maximal per-
centage increase in diameter above baseline. Hyperemic 
stimulus was quantified by baseline and hyperemic shear 
rate (SR = 8 × mean flow velocity/brachial artery diam-
eter) and hyperemic SR area under the curve (AUC). The 
intra-session (1 h apart) and inter-session (30 days apart) 
coefficients of variation were 7.6% (0.3–10.9) and 11.6% 
(2.1–13.2) in a group of 20 healthy volunteers [18].
Renal resistive index
Three velocimetric measurements of the interlobar renal 
arteries (adjacent to the medullary pyramids) in the mes-
orenal area of each kidney were taken with a translum-
bar or anterior ultrasonographic approach. Renal RI was 
calculated in both kidneys according to the formula: (sys-
tolic peak velocity–end diastolic velocity)/systolic peak 
velocity and assessed both at baseline and 5  min after 
administration of GTN 25  μg. Dynamic Renal Resistive 
Index (DRIN) (%) was calculated as: (postGTN RI–base-
line RI) × 100/baseline RI [19]. Intra-observer coefficient 
of variation was 2.1% for RI and 11.6% for DRIN meas-
urements [19].
Arterial tonometry
Arterial tonometry (SphygmoCor, AtCor Medical, Sid-
ney, Australia) was performed according to the interna-
tional recommendations [20]. Central BP was derived 
from radial pressure waveform by means of a validated 
transfer function and averaged on three measurements. 
Augmented pressure was calculated as the difference 
between the second and the first systolic peak, and AIx as 
the ratio between augmented pressure and pulse pressure 
(PP) and normalized at a heart rate of 75 bpm. Time to 
reflection was defined as the total travel time of the pulse-
wave to the periphery and its return. Carotid-femoral 
PWV was calculated as the ratio of the surface distance 
between the two recording sites (direct distance  *  0.8) 
and wave transit time. Three consecutive measurements 
were recorded and the median value was considered.
Humoral parameters of renin‑angiotensin 
and neurohormonal system
Plasma renin activity (PRA) and aldosterone were 
assayed by radioimmunoassay (DiaSorin, Saluggia, Italy). 
Plasma norepinephrine and epinephrine were assayed by 
high performance liquid chromatography.
Urinary 8‑isoprostanes
24-h urinary 8-isoprostane concentration was measured 
by a specific affinity sorbent. Urine samples were centri-
fuged to remove sediment (10 min at 800 g); aliquots of 
supernatants were incubated with 8-isoprostane affin-
ity sorbent for 60  min according to the manufacturer’s 
instructions (Cayman Chemical, Ann Harbor, MI, USA).
Statistical analysis
Statistical analysis was performed using NCSS 8 (NCSS, 
Kaysville, Utah, USA). Data were given as mean ± stand-
ard deviation when normally distributed, as median and 
interquartile range when non-normally distributed, and 
as count and percentages when discrete. Differences 
between groups at baseline were analysed by 2-sided 
paired Student’s t test for normally distributed continu-
ous variables, Wilcoxon rank-sum test for not normally 
distributed continuous variables, or χ2 for categorical 
variables, as appropriate. Differences between Visit 0 
and Visit 1 in the dapagliflozin and HCT treatment arms 
were analysed by repeated measures ANOVA, consider-
ing treatment as between factor and time as within fac-
tor. Bonferroni post hoc comparison test was also used. 
A post hoc sample size calculation was performed con-
sidering FMD  as outcome variable and using the data 
collected in this study. A sample size of 24 patients was 
adequate to demonstrate the detected difference in FMD 
with a power of 0.82 and alpha 0.05.
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A p value ≤ 0.05 was considered statistically significant.
Results
The two groups were comparable for age (dapagliflozin 
57 ±  9 vs HCT 60 ±  8  years, p =  0.29), sex (M/F 11/5 
vs 7/3, p = 0.95) and BMI (30.5 ± 6.7 vs 28.5 ± 4.1 kg/
m2, p = 0.26); HbA1c tended to be lower, even not signif-
icantly, in the HCT arm (56.0 ± 6.8 vs 49.2 ± 9.9 mmol/
mol, 7.3 ± 2.8 vs 6.7 ± 3.1%). Table 1 shows the behav-
iour of serum variables in the study population. Acute 
treatment with dapagliflozin and HCT lowered clinic sys-
tolic BP values by a similar extent, whereas heart rate was 
significantly increased only in the HCT group (p = 0.04 
for the interaction time*treatment).
At baseline, the two groups slightly differed by haem-
atocrit and serum osmolarity (both higher in the dapa-
gliflozin group). Humoral parameters did not vary in the 
two treatment arms, with the exception of serum magne-
sium concentration, which significantly rose (p =  0.003 
for the interaction time*treatment) only in the dapagliflo-
zin group. Both treatments induced a significant rise in 
plasma renin activity, greater for HCT group (p = 0.001 
for the interaction time*treatment), but did not influence 
aldosterone levels, as well as the neuro-hormonal pat-
tern, given that norepinephrine and epinephrine concen-
trations were unmodified.
Table  2 reports urinary parameters before and after 
treatment. As expected, 24 h diuresis significantly raised 
in both groups, whereas urinary glucose excretion 
increased and free water clearance declined only in dapa-
gliflozin group. Noteworthy, free water clearance was 
strongly enhanced only in dapagliflozin treated patients, 
while Na fractional excretion was unmodified in both 
arms. 24  h urinary excretion of electrolytes, including 
magnesium, were unchanged by either treatment.
The behaviour of vascular variables is summarized 
in Table  3 and Fig.  1. Aortic PWV was significantly 
decreased by dapagliflozin but not by HCT (p = 0.03 for 
time*    treatment interaction), whereas central BP values 
and pressure augmentation variables were not signifi-
cantly different. Treatment with dapagliflozin induced an 
increase in FMD (p = 0.02 for the time*treatment inter-
action), while the endothelium-independent brachial vas-
odilation did not vary. Furthermore, a significant increase 
in baseline brachial artery diameter was observed in the 
dapagliflozin arm (p = 0.03 for the time*treatment inter-
action), leading to a reduction in baseline and hyperemic 
shear rate. Finally, considering renal vascular variables, 
RI was significantly decreased after 2-day treatment with 
dapagliflozin (p  =  0.04 for the time*treatment  interac-
tion). None of these parameters were influenced by HCT 
treatment. 
On univariate analysis, performed in the dapagliflo-
zin group, absolute changes in PWV, FMD, and RI were 
not associated with changes in either brachial (r = 0.17, 
p  =  0.74; r  =  0.03, p  =  0.90; r  =  −  0.42, p  =  0.13 
Table 1 Behaviour of serum parameters before and after 2-day treatment with dapagliflozin or hydrochlorothiazide
a p < 0.05 vs V0
b p < 0.05 vs HCT (Bonferroni post hoc comparison)
Dapagliflozin (n = 16) Hydrochlorothiazide (n = 10) p value
(time × treatment 
interaction)Visit 0 Visit 1 Visit 0 Visit 1
Plasma glucose (mmol/l) 7.96 ± 2.47 7.43 ± 2.1b 6.47 ± 1.16 (n = 6) 5.32 ± 0.88
(n = 6)
0.42
Haematocrit (%) 43.0 ± 2.7b 42.6 ± 3.1b 40.7 ± 4.1 40.4 ± 2.4 0.52
Total cholesterol (mmol/l) 4.62 ± 0.76 4.72 ± 1.09b 4.18 ± 0.59 3.87 ± 0.50 0.17
HDL cholesterol (mmol/l) 1.19 ± 0.23 1.24 ± 0.36 1.37 ± 0.24 1.29 ± 0.16 0.30
Triglycerides (mmol/l) 1.40 ± 0.55 1.50 ± 0.81 1.45 ± 0.31 1.16 ± 0.29 0.11
eGFR (ml/min/1.73 m2) 95.7 ± 12.8 93.7 ± 12.6 102.2 ± 6.1 97.8 ± 3.9 0.51
s-sodium (mEq/l) 141.0 ± 2.0 141.1 ± 1.2 139.3 ± 1.9 141.0 ± 2.6 0.13
s-potassium (mEq/l) 4.4 ± 0.3 4.3 ± 0.3 4.5 ± 2.1 4.2 ± 0.4 0.61
s-calcium (mg/dl) 9.6 ± 0.2 9.6 ± 0.3 9.5 ± 0.9 9.7 ± 0.9 0.03
s-chloride (mEq/l) 101.3 ± 2.9 100.3 ± 2.1 101.3 ± 2.9 102.0 ± 0.0 0.17
s-magnesium (mg/dl) 1.92 ± 0.19 2.04 ± 0.17ab 1.98 ± 0.33 1.90 ± 0.27 0.003
s-osmolarity (mOsm/l) 296 ± 5b 296 ± 2 290 ± 5 294 ± 7 0.04
Plasma renin activity (ng/ml/h) 0.50 ± 0.33 1.13 ± 0.97ab 1.09 ± 0.56 4.00 ± 0.06a 0.001
Aldosterone (pg/ml) 12.0 ± 4.7 14.3 ± 7.0 7.4 ± 4.6 3.9 ± 0.3 0.36
Norepinephrine (nmol/l) 414  [175]b 424 [73] 517 [419] 473  [413]a 0.18
Adrenaline (pmol/l) 25 [37] 25 [24] 41 [13] 40 [11] 0.86
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respectively) or aortic systolic BP (r  =  0.08, p  =  0.67; 
r = 0.01, p = 0.96; r = − 0.21, p = 0.47 respectively) or 
to changes in plasma and urinary variables. Systolic BP 
reduction (r = − 0.60, p = 0.02) and aldosterone increase 
(r =  0.70, p =  0.008) were significantly associated with 
increased osmole clearance.
Searching for a putative mechanism involved in the 
specific vascular effects of dapagliflozin, we found that 
Table 2 Behaviour of urinary parameters before and after 2-day treatment with dapagliflozin or hydrochlorothiazide
Data are mean ± SD, or median [IQ]
s serum, u urinary
a p < 0.05 vs V0
b p < 0.05 vs HCT (Bonferroni post hoc comparison). The p value is for time × treatment interaction obtained by repeated measures ANOVA
Dapagliflozin (n = 16) Hydrochlorothiazide (n = 10) p value
(time × treatment 
interaction)Visit 0 Visit 1 Visit 0 Visit 1
Diuresis (ml/24 h) 1400 [750] 2000  [750]a 1250 [150] 2100 [700] 0.47
u-sodium (mEq/24 h) 175 [107] 180 [57] 129 [96] 141 [173] 0.31
u-potassium (mEq/24 h) 60 [37] 64 [36] 56 [23] 59 [49] 0.10
u-calcium (mg/24 h) 220 [238] 158 [229] 250 [120] 93 [260] 0.47
u-chloride (mEq/24 h) 183 [113] 167 [79] 105 [121] 130 [163] 0.30
u-magnesium (mg/24 h) 70 [86] 72 [88] 100 [36] 78 [103] 0.34
u-osmolarity (mOsm/l) 687 ± 325 877 ± 230b 512 ± 76 377 ± 179 0.15
Glycosuria (mg/24 h) 406 [4224] 70,630 [40,110]ab 100 [84] 45 [135] < 0.001
Osmolar clearance (ml/24 h) 2369 [3509] 5971  [3251]a 1982 [664] 2063 [2922] 0.28
Free water clearance (ml/24 h) − 1119 [3441] − 4221  [3549]a − 757 [538] 36 [2222] 0.17
Na fractional excretion 0.89 ± 0.32 0.97 ± 0.34 0.62 ± 0.17 0.79 ± 0.07 0.72
Table 3 Behaviour of  blood pressure and  vascular parameters before  and after  2-day treatment with  dapagliflozin or 
hydrochlorothiazide
a p < 0.05 vs V0
b p < 0.05 vs HCT (Bonferroni post hoc comparison). The p value is for time × treatment interaction obtained by repeated measures ANOVA
Dapagliflozin (n = 16) Hydrochlorothiazide (n = 10) p value
(time × treatment 
interaction)Visit 0 Visit 1 Visit 0 Visit 1
Office systolic BP (mmHg) 130.6 ± 12.8 125.4 ± 11.2 137.2 ± 12.6 128.8 ± 11.2a 0.44
Office diastolic BP (mmHg) 75.3 ± 6.3 74.1 ± 6.9 76.1 ± 9.2 69.2 ± 7.3 0.06
Office pulse pressure (mmHg) 55.3 ± 11.2 51.3 ± 12.1 61.1 ± 10.4 59.6 ± 10.5 0.45
Pulse wave velocity (m/s) dir*0.8 10.1 ± 1.6 8.8 ± 1.6ab 11.0 ± 2.8 11.1 ± 2.6 0.03
Augmentation index (%) 30.2 ± 9.3 29.3 ± 11.2b 26.2 ± 5.3 22.1 ± 6.6 0.22
Augmentation index@75 (%) 26.3 ± 7.5 24.8 ± 10.1b 22.4 ± 5.8 19.6 ± 5.1 0.58
Central systolic BP (mmHg) 119.7 ± 10.6 116.0 ± 10.7 125.5 ± 11.1 115.2 ± 11.5 0.17
Central pulse pressure (mmHg) 44.2 ± 8.2 40.8 ± 11.5 48.4 ± 9.5 45.0 ± 10.3 0.99
Mean BP (mmHg) 94.4 ± 7.8 92.5 ± 6.6 97.5 ± 9.2 89.5 ± 7.5 0.11
Augmented pressure (mmHg) 13.6 ± 6.1 12.6 ± 7.5 12.8 ± 4.9 10.5 ± 5.1 0.44
Heart rate (bpm) 67.0 ± 12.0 65.5 ± 11.7b 67.1 ± 8.7 69.8 ± 9.3 0.04
Brachial artery diameter (mm) 4.29 ± 0.88b 4.46 ± 1.07a 4.52 ± 0.54 4.49 ± 0.51 0.03
Flow-mediated dilation (%) 2.81 ± 2.25 4.02 ± 2.09ab 2.99 ± 0.91 2.63 ± 1.01 0.02
Baseline shear rate  (s−1) 199 ± 78b 140 ± 66a 279 ± 108 301 ± 118 < 0.001
Hyperemic shear rate  (s−1) 787 ± 292 536 ± 337ab 927 ± 299 889 ± 399 0.05
Response to GTN (%) 6.36 ± 3.48 6.16 ± 2.87 4.11 ± 2.83 3.58 ± 2.89 0.85
Renal resistive index 0.62 ± 0.04 0.59 ± 0.05a 0.62 ± 0.05 0.62 ± 0.04 0.04
Dynamic renal resistive index (%) − 6.10 ± 3.70 − 2.27 ± 4.39 − 2.96 ± 3.94 − 0.91 ± 3.8 0.43
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24  h urinary isoprostanes were significantly reduced by 
dapagliflozin (from 1659  ±  1029 to 1157  ±  663  pg/ml, 
p = 0.04) but not by HCT. Urinary 8-isoprostanes reduc-
tion was significantly associated with serum magnesium 
increase (r  =  −  0.81, p  <  0.001) and urinary glucose 
excretion (r = − 0.57, p = 0.03).
Discussion
The main finding of this pilot study, designed to explore 
the acute effects of dapagliflozin on systemic and renal 
vascular function, is a significant improvement in 
endothelial function, arterial stiffness and renal resistive 
index, occurring in the presence of stable blood glucose 
and natriuresis; a significant reduction in BP and oxi-
dative stress was also found. A minor, albeit intriguing 
novel observation is a raise in serum magnesium concen-
trations, not coupled with a reduced urinary excretion. 
The study also confirms the lack of variation in the adr-
energic tone; surprisingly, despite the claimed natriuretic 
effect of these compounds, natriuresis is unmodified too.
Effect of dapagliflozin on systemic vascular function
We demonstrate here that dapagliflozin is able to induce 
a rapid improvement of conduit artery function, meas-
ured as FMD. These results are likely specific for SGLT2 
inhibitors, since were not replicated in the HCT arm, 
as reported in previous studies [21]. Interestingly, this 
effect occurred in the presence of unchanged brachial 
artery diameter, hyperemic stimulus and response to 
GTN, indicating a selective positive effect of dapagliflo-
zin on the endothelium, which was previously demon-
strated only in animal models and after longer duration 
of treatments. Chronic therapy with SGLT2 inhibitors 
reverses vascular dysfunction by reducing oxidative 
stress in aortic rings from streptozotocin-treated rats 
[22] and from db/db rats [23], and chronically, but not 
acutely, enhances coronary vasodilation to NO donors 
in coronary arteries of diabetic mice [24]. Our study 
provides the first evidence in humans that dapagliflo-
zin improves FMD and reduces oxidative stress; if con-
firmed in longer, placebo-controlled trials, the former 
effect might play a role in the reduction of cardiovascular 
risk induced by SGLT2 inhibitors [25, 26], while the lat-
ter could participate in the observed acute improvement 
in vascular function. Indeed, hyperglycemia-induced 
endothelial dysfunction is prevented by acute antioxidant 
administration [27]. Conversely, RAAS does not seem to 
mediate these acute vascular effects; the small increase 
in PRA we have observed with both treatments is con-
ceivably a counter-regulatory response to the increased 
24 h diuresis, as already reported [7]. Noteworthy, since 
both sympathetic activation [28] and hyperglycemia 
[29] may induce endothelial dysfunction, the presence 
of unchanged glucose and catecholamines levels after 
dapagliflozin treatment suggests a direct effect of dapa-
gliflozin on the vascular endothelium. However, a sympa-
tho-inhibitory effect of dapagliflozin cannot be definitely 
excluded since, after an acute reduction in BP, a barore-
flex increase in catecholamines and heart rate might have 
been expected. The lack of HR increase in the dapagli-
flozin arm, at variance with HCT, reinforces the above-
reported hypothesis. Dedicated studies, performed with 
more sophisticated and reproducible techniques [30], are 
needed to elucidate this crucial issue, though some neu-
tral results were found in type 1 diabetic patients [31] and 
in animals [32].
In agreement with the reported restoration of 
endothelium-dependent vasodilation, the results 
Fig. 1 Box plots representing the behaviour of flow-mediated dilation (a), pulse wave velocity (b) and resting renal resistive index (c) in the study 
population before (in white) and after (in grey) 2-day treatment with dapagliflozin or hydrochlorothiazide
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regarding arterial stiffness are also of interest. The sig-
nificant reduction in aortic PWV induced by dapagli-
flozin occurred after only 2  days of treatment and was 
independent of BP reduction, since was not observed in 
patients treated with HCT, in which a similar BP reduc-
tion was obtained. This finding suggests that dapagli-
flozin may act on the functional component of arterial 
stiffness, which is under the control of endothelium-
mediated mechanisms especially in type 2 diabetes 
[12]. Cherney and coauthors demonstrated an effect of 
8-week treatment with SGLT2 inhibitors on aortic stiff-
ness in type 1 diabetic patients during hyperglicemic but 
not during euglycemic clamp [32]; however, these results 
are hardly comparable with those obtained in our study, 
for the different study population, treatment duration 
and experimental conditions.
In parallel with FMD findings, if a sustained reduction 
in PWV will be confirmed by longer trials, this may well 
explain a reduction in cardiovascular events [33]; in this 
view, studies with longer treatment duration are currently 
ongoing [34] to confirm whether a long-lasting effect on 
atherosclerosis and large artery stiffness does exist. The 
reduction in oxidative stress, that we explored as second-
ary outcome of our study, can be regarded as a unifying 
hypothesis of the positive effects on the vasculature.
Effect of dapagliflozin on renal vasculature
Two-day dapagliflozin treatment, but not HCT, induced 
a significant decrease in renal RI. This index has been 
related to renal arteriolosclerosis and proposed as an 
integrated index of arterial compliance, pulsatility and 
downstream microvascular impedance [35]. However, 
there is an ongoing debate about the clinical significance 
and the physio-pathological meaning of this simple ultra-
sound parameter, since some evidence suggest that renal 
RI is influenced by systemic hemodynamics, rather than 
by renal vascular resistance [36]. Furthermore, recent 
data from our group suggest that in morbid obesity, a 
condition characterized by renal hyperfiltration and 
increased renal plasma flow, RI is directly correlated with 
renal plasma flow and inversely correlated with renal vas-
cular resistance, and is reduced after bariatric surgery 
proportionally to renal plasma flow, suggesting that in 
these conditions RI is an index of hyperperfusion rather 
than of arteriolosclerosis [37, 38]. The effect of 8-week 
treatment with SGLT2 inhibitors on renal hemodynamics 
(measured by classical techniques, i.e. inulin and para-
aminohippurate clearance) has been so far explored only 
in type 1 diabetic patients [6, 39], where empagliflozin 
was able to significantly reduce hyperfiltration and hyper-
perfusion, possibly restoring tubuloglomerular feed-
back and increasing afferent arteriolar resistance. Thus, 
it is conceivable that the significant, acute RI reduction 
induced by dapagliflozin is explained by the reduction in 
renal plasma flow exerted by SGLT2 inhibition, blocking 
proximal tubule glucose and sodium reabsorption, which 
leads to increased sodium delivery to the macula densa 
and restoration of tubuloglomerular feedback. The fast 
time course of the effect and the broadly unchanged cen-
tral pulse pressure exclude an effect of renal arterioscle-
rosis, as well as reduced systemic pulsatility, as possible 
mechanisms of acute RI reduction.
The assessment of renal vascular function by static or 
dynamic ultrasound imaging has recently emerged as an 
appealing target for identifying subtle vascular alterations 
responsible for the development of diabetic nephropathy 
[40]. High RI has a negative prognostic value in diabetic 
patients in terms of progression of renal disease [41] and 
it is associated with higher all-cause mortality in patients 
with chronic kidney disease [42]; treatment with RAS 
blockers, drugs able to modify the clinical course of dia-
betic nephropathy, reduces RI by reducing renal plasma 
flow through vasodilation of the efferent arteriole [43]. 
The correction of renal hyperperfusion, which is adjunc-
tive and complementary to RAAS-blockade, concurs to 
renal protection exerted by dapagliflozin [7, 44]. In the 
present study DRIN, calculated as the reduction in RI 
rapidly induced by sublingual administration of low-dose 
GTN, was increased, indicating a reduced vasodilation to 
nitrates. DRIN might represent a marker of renal vasodi-
lating capacity and a predictor of microalbuminuria 
onset in type 2 diabetic individuals [19, 45]; in the present 
study, dapagliflozin effects on DRIN are probably masked 
by the above-described effects on renal plasma flow.
Effect of dapagliflozin on electrolytes balance
A novel observation coming from our data is to charac-
terize for the first time as dapagliflozin acutely acts as a 
purely “glucoretic” compound; in other words, beside gly-
cosuria, it increases free water excretion without modify-
ing the urinary electrolyte profile.
A common, and likely incorrect concept, is that SGLT2 
inhibitors exert a beneficial natriuretic effect, even 
though few studies have so far measured natriuresis dur-
ing SGLT2 inhibition in type 2 diabetes [7]. Recently, a 
transient increase in urinary sodium and chloride excre-
tion has been reported with empagliflozin [7, 44]; we 
could not confirm this observation with dapagliflozin. 
The lack of variation in natriuresis, even after a 2-day 
treatment, supports the hypothesis of an increased 
expression and/or functional activity of other sodium 
transporters that might account for an immediately 
increased distal Na reabsorption. It is unlikely that the 
lack of change in natriuresis is attributable to the baseline 
small difference in serum osmolarity, more likely influ-
enced by baseline difference in haematocrit.
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Furthermore, acute variations in serum potassium levels 
were not observed in the present study. In a similar exper-
imental setting, empagliflozin induces a modest, albeit 
significant increase in serum potassium levels [7, 44]. We 
cannot exclude that this different behaviour might be due 
to the different SGLT2 selectivity of the two drugs; how-
ever, this selective action on the free water pool can be 
regarded as a clinically advantageous effect respect to diu-
resis induced by classic thiazide compounds.
Another small mechanistic contribution of the present 
study is to show here that an increased serum magnesium 
level following SGLT2 inhibition, recently reported by an 
ample meta-analysis [45], is an immediate effect. Interest-
ingly, magnesium in the high-normality range, is associ-
ated with a lower cardiovascular risk [46]. Furthermore, 
magnesium supplementation exerts favorable effects on 
endothelial function in individuals at risk for diabetes 
[47, 48], suggesting another possible mechanism through 
which SGLT2 inhibitors achieve vascular protection.
Some limitations of the present study should be acknowl-
edged. First, this is a pilot study; though performed in a 
carefully selected population, the promising beneficial 
effects of dapagliflozin on endothelial function should 
be confirmed in larger cohorts and by randomized clini-
cal trials. This is particularly relevant, since adjustment 
for known determinants of vascular function (i.e. brachial 
artery diameter for FMD), crucial for the interpretation of 
our findings [49], was not possible in the present study due 
to the small sample size. Second, before the described acute 
vascular effects can translate to an effective reduction of 
the cardiovascular risk, a demonstration of a long-lasting 
improvement in vascular function is necessary.
Conclusions
In type 2 diabetic individuals, acute dapagliflozin admin-
istration has direct, beneficial effects on systemic and 
renal vasculature. These pleiotropic effects, which are 
conceivably BP- and glucose-independent, could repre-
sent a mechanism for cardiovascular protection for this 
drug class [50]. Furthermore, the rapid osmotic diure-
sis with neutral effects on electrolyte balance qualifies 
SGLT2 inhibitors as a valid, safe and intriguing alterna-
tive to thiazide diuretics in type 2 diabetic patients.
Abbreviations
AUC: area under the curve; AIx: augmentation index; DRIN: dynamic renal 
resistive index; FMD: flow-mediated dilation; GTN: glyceryl trinitrate; HCT: 
hydrochlorothiazide; NO: nitric oxide; PP: pulse pressure; PRA: plasma renin 
activity; PWV: pulse-wave velocity; RAAS: renin–angiotensin–aldosterone 
system; RI: resistive index; SGLT2: sodium-glucose co-transporter-2; SR: shear 
rate; T2D: type 2 diabetes.
Authors’ contributions
AS designed the study, analysed data and wrote the manuscript. LGi 
performed the studies. MS and EV helped to perform the studies. ST revised 
the manuscript. LG contributed to design the study, revised the manuscript. 
RMB performed all the vascular determinations, analysed data and wrote the 
manuscript. All authors read and approved the final manuscript.
Author details
1 Department of Surgical, Medical, Molecular and Critical Area Pathology, 
I-56126 Pisa, Italy. 2 Department of Clinical and Experimental Medicine, Univer-
sity of Pisa, Pisa, Italy. 
Acknowledgements
We thank all the patients participating in the study.
Competing interests
The authors declare that they have no competing interests.
Availability of data and materials
The datasets used and/or analysed during the current study are available from 
the corresponding author on reasonable request.
Consent for publication
Not applicable.
Ethics approval and consent to participate
The protocol was approved by the local Ethics Committee and registered in 
the Registry of the Italian Drug Agency (Agenzia Italiana del Farmaco, AIFA,# 
772/2015). All participants signed a written informed consent.
Funding
The study has been supported by an unconditioned grant from Astra Zeneca. 
The sponsor did not have any role in analysing data or writing the paper.
Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in pub-
lished maps and institutional affiliations.
Received: 18 August 2017   Accepted: 15 October 2017
References
 1. Ivy JR, Bailey MA. Pressure natriuresis and the renal control of arterial 
blood pressure. J Physiol. 2014;592:3955–67.
 2. Cai Z, Xin J, Pollock DM, Pollock JS. Shear stress-mediated NO produc-
tion in inner medullary collecting duct cells. Am J Physiol Renal Physiol. 
2000;279:F270–4.
 3. Hyndman KA, Pollock JS. Nitric oxide and the A and B of endothelin of 
sodium homeostasis. Curr Opin Nephrol Hypertens. 2013;22:26–31.
 4. Cowley AW Jr, Abe M, Mori T, O’Connor PM, Ohsaki Y, Zheleznova NN. 
Reactive oxygen species as important determinants of medullary 
flow, sodium excretion, and hypertension. Am J Physiol Renal Physiol. 
2015;308:F179–97.
 5. Ferrannini E, Solini A. SGLT2 inhibition in diabetes mellitus: rationale and 
clinical prospects. Nat Rev Endocrinol. 2012;8:495–502.
 6. Cherney DZ, Perkins BA, Soleymanlou N, Maione M, Lai V, Lee A, et al. 
Renal hemodynamic effect of sodium-glucose cotransporter 2 inhibition 
in patients with type 1 diabetes mellitus. Circulation. 2014;129:587–97.
 7. Heise T, Jordan J, Wanner C, Heer M, Macha S, Mattheus M, et al. 
Acute pharmacodynamic effects of empagliflozin with and without 
diuretic agents in patients with type 2 diabetes mellitus. Clin Ther. 
2016;38:2248–64.
 8. Sha S, Polidori D, Heise T, Natarajan J, Farrell K, Wang SS, et al. Effect of 
the sodium glucose co-transporter 2 inhibitor canagliflozin on plasma 
volume in patients with type 2 diabetes mellitus. Diabetes Obes Metab. 
2014;16:1087–95.
 9. Pavlov TS, Staruschenko A. Involvement of ENaC in the development of 
salt-sensitive hypertension. Am J Physiol Renal Physiol. 2017;313:F135–40.
 10. Rahman A, Kittikulsuth W, Fujisawa Y, Sufiun A, Rafiq K, Hitomi H, et al. 
Effects of diuretics on sodium-dependent glucose cotransporter 2 
Page 9 of 9Solini et al. Cardiovasc Diabetol  (2017) 16:138 
inhibitor-induced changes in blood pressure in obese rats suffering from 
the metabolic syndrome. J Hypertens. 2016;34:893–906.
 11. Shin SJ, Chung S, Kim SJ, Lee EM, Yoo YH, Kim JW, et al. Effect of 
sodium-glucose co-transporter 2 inhibitor, dapagliflozin, on renal renin-
angiotensin system in an animal model of type 2 diabetes. PLoS ONE. 
2016;11:e0165703.
 12. Bruno RM, Penno G, Daniele G, Pucci L, Lucchesi D, Stea F, et al. Type 
2 diabetes mellitus worsens arterial stiffness in hypertensive patients 
through endothelial dysfunction. Diabetologia. 2012;55:1847–55.
 13. Matthews EL, Brian MS, Ramick MG, Lennon-Edwards S, Edwards DG, 
Farquhar WB. High dietary sodium reduces brachial artery flow-mediated 
dilation in humans with salt-sensitive and salt-resistant blood pressure. J 
Appl Physiol (1985). 2015;118:1510–5.
 14. Cherney DZ, Reich HN, Jiang S, Har R, Nasrallah R, Hébert RL, et al. Hyper-
filtration and effect of nitric oxide inhibition on renal and endothelial 
function in humans with uncomplicated type 1 diabetes mellitus. Am J 
Physiol Regul Integr Comp Physiol. 2012;303:R710–8.
 15. Eriksson L, Nystrom T. Antidiabetic agents and endothelial dysfunction–
beyond glucose control. Basic Clin Pharmacol Toxicol. 2015;117:15–25.
 16. Kasichayanula S, Liu X, Lacreta F, Griffen SC, Boulton DW. Clinical 
pharmacokinetics and pharmacodynamics of dapagliflozin, a selective 
inhibitor of sodium-glucose co-transporter type 2. Clin Pharmacokinet. 
2014;53:17–27.
 17. Bruno RM, Rossi L, Fabbrini M, Duranti E, Di Coscio E, Maestri M, et al. 
Renal vasodilating capacity and endothelial function are impaired in 
patients with obstructive sleep apnea syndrome and no traditional 
cardiovascular risk factors. J Hypertens. 2013;31:1456–64.
 18. Ghiadoni L, Faita F, Salvetti M, Cordiano C, Biggi A, Puato M, et al. Assess-
ment of flow-mediated dilation reproducibility: a nationwide multicenter 
study. J Hypertens. 2012;30:1399–405.
 19. Bruno RM, Daghini E, Landini L, Versari D, Salvati A, Santini E, et al. 
Dynamic evaluation of renal resistive index in normoalbuminuric patients 
with newly diagnosed hypertension or type 2 diabetes. Diabetologia. 
2011;54:2430–9.
 20. Van Bortel LM, Laurent S, Boutouyrie P, Chowienczyk P, Cruickshank JK, 
De Backer T, et al. Expert consensus document on the measurement of 
aortic stiffness in daily practice using carotid-femoral pulse wave velocity. 
J Hypertens. 2012;30:445–8.
 21. Ghiadoni L, Taddei S, Virdis A. Hypertension and endothelial dysfunction: 
therapeutic approach. Curr Vasc Pharmacol. 2012;10:42–60.
 22. Oelze M, Kroller-Schon S, Welschof P, Jansen T, Hausding M, Mikhed 
Y, et al. The sodium-glucose co-transporter 2 inhibitor empagliflozin 
improves diabetes-induced vascular dysfunction in the streptozotocin 
diabetes rat model by interfering with oxidative stress and glucotoxicity. 
PLoS ONE. 2014;9:e112394.
 23. Lin B, Koibuchi N, Hasegawa Y, Sueta D, Toyama K, Uekawa K, et al. 
Glycemic control with empagliflozin, a novel selective SGLT2 inhibitor, 
ameliorates cardiovascular injury and cognitive dysfunction in obese and 
type 2 diabetic mice. Cardiovasc Diabetol. 2014;13:148.
 24. Han Y, Cho YE, Ayon R, Guo R, Youssef KD, Pan M, et al. SGLT inhibitors 
attenuate NO-dependent vascular relaxation in the pulmonary artery 
but not in the coronary artery. Am J Physiol Lung Cell Mol Physiol. 
2015;309:L1027–36.
 25. Luscher TF, Taddei S, Kaski JC, Jukema JW, Kallend D, Münzel T, et al. 
Vascular effects and safety of dalcetrapib in patients with or at risk of 
coronary heart disease: the dal-VESSEL randomized clinical trial. Eur Heart 
J. 2012;33:857–65.
 26. Inaba Y, Chen JA, Bergmann SR. Prediction of future cardiovascular 
outcomes by flow-mediated vasodilatation of brachial artery: a meta-
analysis. Int J Cardiovasc Imaging. 2010;26:631–40.
 27. Title LM, Cummings PM, Giddens K, Nassar BA. Oral glucose loading 
acutely attenuates endothelium-dependent vasodilation in healthy 
adults without diabetes: an effect prevented by vitamins C and E. J Am 
Coll Cardiol. 2000;36:2185–91.
 28. Bruno RM, Ghiadoni L, Seravalle G, Dell’oro R, Taddei S, Grassi G. Sympa-
thetic regulation of vascular function in health and disease. Front Physiol. 
2012;3:284.
 29. Greyling A, Schreuder TH, Landman T, Draijer R, Verheggen RJ, Hopman 
MT, et al. Elevation in blood flow and shear rate prevents hyperglycemia-
induced endothelial dysfunction in healthy subjects and those with type 
2 diabetes. J Appl Physiol. 1985;2015(118):579–85.
 30. Grassi G, Seravalle G, Dell’Oro R, Arenare F, Facchetti R, Mancia G. 
Reproducibility patterns of plasma norepinephrine and muscle sym-
pathetic nerve traffic in human obesity. Nutr Metab Cardiovasc Dis. 
2009;19:469–75.
 31. Cherney DZ, Perkins BA, Soleymanlou N, Har R, Fagan N, Johansen OE, 
et al. The effect of empagliflozin on arterial stiffness and heart rate varia-
bility in subjects with uncomplicated type 1 diabetes mellitus. Cardiovasc 
Diabetol. 2014;13:28.
 32. Kusaka H, Koibuchi N, Hasegawa Y, Ogawa H, Kim-Mitsuyama S. Empagli-
flozin lessened cardiac injury and reduced visceral adipocyte hypertro-
phy in prediabetic rats with metabolic syndrome. Cardiovasc Diabetol. 
2016;15:157.
 33. Ben-Shlomo Y, Spears M, Boustred C, May M, Anderson SG, Benjamin EJ, 
et al. Aortic pulse wave velocity improves cardiovascular event predic-
tion: an individual participant meta-analysis of prospective observational 
data from 17,635 subjects. J Am Coll Cardiol. 2014;63:636–46.
 34. Tanaka A, Murohara T, Taguchi I, Eguchi K, Suzuki M, Kitakaze M, et al. 
Rationale and design of a multicenter randomized controlled study to 
evaluate the preventive effect of ipragliflozin on carotid atherosclerosis: 
the PROTECT study. Cardiovasc Diabetol. 2016;15:133.
 35. Krumme B. Renal doppler sonography–update in clinical nephrology. 
Nephron Clin Pract. 2006;103:c24–8.
 36. O’Neill WC. Renal resistive index: a case of mistaken identity. Hyperten-
sion. 2014;64:915–7.
 37. Vitolo E, Santini E, Salvati A, Volterrani D, Duce V, Bruno RM, et al. Meta-
bolic and hormonal determinants of glomerular filtration rate and renal 
hemodynamics in severely obese individuals. Obes Facts. 2016;9:310–20.
 38. Bruno RM, Vitolo E, Giannini L, Taddei S, Ghiadoni L, Solini A. Effect of 
bariatric surgery on vascular and renal biomarkers in morbidly obese, 
normotensive, non-diabetic patients. J Hypertens. 2016;34:e88–9.
 39. Skrtic M, Yang GK, Perkins BA, Soleymanlou N, Lytvyn Y, von Eynatten M, 
et al. Characterisation of glomerular haemodynamic responses to SGLT2 
inhibition in patients with type 1 diabetes and renal hyperfiltration. 
Diabetologia. 2014;57:2599–602.
 40. Bruno RM, Reesink KD, Ghiadoni L. Advances in the non-invasive assess-
ment of vascular dysfunction in metabolic syndrome and diabetes: 
focus on endothelium, carotid mechanics and renal vessels. Nutr Metab 
Cardiovasc Dis. 2017;27:121–8.
 41. Nosadini R, Velussi M, Brocco E, Abaterusso C, Carraro A, Piarulli F, et al. 
Increased renal arterial resistance predicts the course of renal function in 
type 2 diabetes with microalbuminuria. Diabetes. 2006;55:234–9.
 42. Toledo C, Thomas G, Schold JD, Arrigain S, Gornik HL, Nally JV, et al. Renal 
resistive index and mortality in chronic kidney disease. Hypertension. 
2015;66:382–8.
 43. Leoncini G, Martinoli C, Viazzi F, Ravera M, Parodi D, Ratto E, et al. Changes 
in renal resistive index and urinary albumin excretion in hypertensive 
patients under long-term treatment with lisinopril or nifedipine GITS. 
Nephron. 2002;90:169–73.
 44. Heise T, Jordan J, Wanner C, Heer M, Macha S, Mattheus M, et al. Phar-
macodynamic effects of single and multiple doses of empagliflozin in 
patients with type 2 diabetes. Clin Ther. 2016;38:2265–76.
 45. Tang H, Zhang X, Zhang J, Li Y, Del Gobbo LC, Zhai S, et al. Elevated 
serum magnesium associated with SGLT2 inhibitor use in type 2 diabetes 
patients: a meta-analysis of randomised controlled trials. Diabetologia. 
2016;59:2546–51.
 46. Del Gobbo LC, Imamura F, Wu JH, de Oliveira Otto MC, Chiuve SE, Mozaf-
farian D. Circulating and dietary magnesium and risk of cardiovascular 
disease: a systematic review and meta-analysis of prospective studies. Am 
J Clin Nutr. 2013;98:160–73.
 47. Cosaro E, Bonafini S, Montagnana M, Danese E, Trettene MS, Minuz P, 
et al. Effects of magnesium supplements on blood pressure, endothe-
lial function and metabolic parameters in healthy young men with 
a family history of metabolic syndrome. Nutr Metab Cardiovasc Dis. 
2014;24:1213–20.
 48. Maier JA. Endothelial cells and magnesium: implications in atherosclero-
sis. Clin Sci (Lond). 2012;122:397–407.
 49. Atkinson G. The dependence of FMD% on baseline diameter: a problem 
solved by allometric scaling. Clin Sci (Lond). 2013;125:53–4.
 50. Zinman B, Wanner C, Lachin JM, Fitchett D, Bluhmki E, Hantel S, et al. 
Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. 
N Engl J Med. 2015;373:2117–28.
